Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Artiva Biotherapeutics, Inc. (ARTV)

Artiva Q2 net loss widens to $25.0 million; cash totals $349.4 million

Negative Impact 3 of 5 earnings Written later

Artiva Biotherapeutics reported a second-quarter 2026 net loss of $25.0 million, up from $21.3 million a year earlier, as research and development expenses rose to $21.9 million from $17.9 million. The company said cash, cash equivalents and investments of $349.4 million are expected to fund operations into 2029, and it plans to start a Phase 3 trial of AlloNK in refractory rheumatoid arthritis in the second half of 2026.

Key points

  • Net loss of $25.0 million for the quarter ended June 30, 2026, versus $21.3 million for the same quarter of 2025
  • Research and development expenses of $21.9 million, compared with $17.9 million a year earlier
  • Cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029
  • Phase 3 randomized trial of AlloNK plus rituximab in about 150 refractory RA patients to begin in the second half of 2026

The filing

CompanyArtiva Biotherapeutics, Inc. (ARTV)
Form8-K, current report
Filed with the SECAug 6, 2026, 4:09 PM ET
Accession number0001193125-26-337986

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.